Objective We evaluated the association between the Fas-670A/G and the Fas ligand FasL IVS2nt 124 A/G polymorphisms and the risk of pre-eclampsia and its complications.
Introduction
Pre-eclampsia is one of the main causes of maternal and fetal morbidity and mortality worldwide. It is characterised by elevated maternal blood pressure and proteinuria after 20 weeks of pregnancy. 1 Understanding of it physiopathology remains unresolved, with symptoms disappearing after the delivery of the baby. Numerous studies have demonstrated an increased apoptosis level of placental villous trophoblasts in pregnancies complicated by pre-eclampsia. [2] [3] [4] The Fas receptor (Fas) and Fas ligand (FasL) system is an important extrinsic pathway implicated in apoptosis. During normal pregnancy, placental trophoblasts expressing FasL interact with Fas on activated T lymphocytes, which leads to T cell apoptosis. Consequently, apoptosis of maternal lymphocytes prevents these cells from recognising and destroying cytotrophoblasts, and thus allows for normal trophoblast invasion, leading to placental development and growth. [5] [6] [7] [8] [9] Interestingly, serum from women with pre-eclampsia reduces trophoblast viability in vitro. This effect was enhanced when cells were treated with an anti-Fas antibody and reversed when a blocking anti-Fas ligand antibody was added. 10 The Fas and FasL genes are located on chromosomes 10q24.1 and 1q23, respectively. [11] [12] [13] An A to G substitution at position −670 (Fas A-670G) is located in the transcriptional start site of the gene.
14 This polymorphism is associated with reduced Fas expression in maternal lymphocytes which may result in decreased apoptosis of these cells. 15 In addition, a polymorphism in the FasL gene, an A to G substitution at position 124 of intron 2 (FasL INV2nt A 124G), may affect the expression of FasL gene, but this remains to be confirmed. 11, 12, 16 Four studies have reported an association between the Fas-670G allele and pre-eclampsia in Italian, American, Egyptian and Iranian (Southeast of Iran) populations, 15, [17] [18] [19] but one study found no association in northern Iran. 20 Also, no association was found between the FasL INV2nt A 124G and pre-eclampsia in Italian and Egyptian populations in small cohorts. 17, 19 One of the severe complications of pre-eclampsia is the haemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome. 21 Interestingly, Fas-670G has been associated with a higher risk of HELLP syndrome during pregnancy, but as yet, this has not been demonstrated in the context of pre-eclampsia. 22 As population genetic analyses may differ depending on the ethnicity, the aim of the present investigation was to evaluate the association of Fas A-670G and FasL INV2nt A 124G polymorphisms with the risk of pre-eclampsia in Tunisian women.
Methods

Study design and subjects
This is a retrospective case-control study involving 300 unrelated women with pre-eclampsia and 300 age-matched women with normal pregnancies. The subjects were recruited between May 2012 and June 2014 from the outpatient antenatal care clinic of the Farhat Hached University Hospital (Sousse, central Tunisia), Fattouma Bourguiba University Hospital (Monastir, central Tunisia), Taher Sfar University Hospital (Mahdia, eastern Tunisia) and Gafsa Hospital (southern Tunisia). Pre-eclampsia was defined as gravid hypertension [systolic blood pressure (BP) ≥140 mmHg and diastolic BP ≥ 90 mmHg] with significant proteinuria (≥300 mg/24 hours) assessed after 20 weeks of pregnancy. Severe pre-eclampsia was defined as systolic BP (SBP) ≥ 160 or diastolic BP (DBP) ≥ 110 mmHg and proteinuria of ≥3 + by dipstick or ≥500 mg/24 hours. Eclampsia was defined as a convulsive episode occurring in the presence of pre-eclampsia, provided that there was no other cause of seizures. 21 The women included in this study had no other known pathologies apart from pre-eclampsia. Infant birth complications included in our analyses were fetal intrauterine growth restriction (IUGR) and fetal death. In pre-eclampsia cases, two circulating hepatic enzymes were measured, aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT), as they are components of the HELLP syndrome. Indeed, the diagnosis of the HELLP syndrome is characterised by the presence of aspartate aminotransferase (ASAT) and (ALAT) ˃40 U/l, low platelets <125 000/mm 3 and increased free haemoglobin ˃30 mg/ml.
Women in the control group were recruited from the same hospital and on the same day as pre-eclampsia cases. They had no known personal or family history of hypertension or pre-eclampsia. The ethics committee of the hospital Farhat Hached Sousse approved the study protocol and both pre-eclampsia cases and control women gave written informed consent to their participate in this project. Participant demographic data and clinical characteristics were collected from a designed questionnaire (see Appendix S1) and medical records (Table 1) . Core outcome sets and patient involvement are not relevant to this study.
DNA extraction
On the day of delivery, 5 ml of venous blood was collected in EDTA-anticoagulant tubes from each participant. Blood was centrifuged at 1500 9 g for 10 minutes. Plasma was isolated, genomic DNA was extracted from peripheral blood leucocytes using the salting-out method 23 and samples were stored at À20°C for further analysis.
Fas and Fas ligand genotyping
Fas (Fas A-670G, rs1800682) and FasL (FasL INV2nt A 124G, rs5030772) polymorphisms were identified by the PCR-RFLP method. 24 The target fragments containing these two polymorphisms were amplified by the primers: for the Fas A-670G: 5 0 -ATAGCTGGGGCTATGCGATT-3 0 (forward) and 5 0 -CATTTGACTGGGCTGTCCAT-3 0 (reverse); for FasL INV2nt A 124G : 5 0 -GCAGTTCAGACCTA CATGATTAGGAT-3 0 (forward) and 5 0 -CCAGATACAGA CCTGTTAAATGGGC-3 0 (reverse). 17 For PCR amplification, the reaction mixture consisted of 2.5 mcl of DNA sample, 0.5 lM of each primer, 109 PCR buffer, 1.5 mM of MgCl 2 , 0.5 U of Taq DNA polymerase (Invitrogen), 0.2 mM of each dNTP and water was added to a final volume of 20 mcl. The polymorphisms were identified via PCR product sizes on agarose gel electrophoresis. To detect polymorphisms, the samples were denatured at 95°C for 5 minutes, followed by 35 cycles of denaturation at 94°C for 30 seconds, annealing at 59°C for 30 seconds and extension at 72°C for 30 seconds. The samples were incubated at 72°C for an additional 5 minutes for final extension. The amplified PCR products were 193 and 230 bp for −670 A > G and IVS2nt 124 A > G, respectively. The ScrFI and FokI restriction enzymes were used to distinguish the −670 A > G and IVS2nt 124 A > G polymorphisms, respectively, resulting in 136-and 57-bp fragments for the −670G allele and 180-and 50-bp fragments for the IVS2nt 124 G allele. 17 
Statistical analysis
Statistical analysis was performed on SPSS v21.0 (SPSS Inc., Chicago, IL, USA). Categorical and continuous data were expressed as percentages of total or as mean AE SD, respectively. Differences in means were determined using the Student t test for continuous variables and Fisher's exact test for categorical variables. Inter-group significance was assessed using Fisher's exact test. Genotypes were tested for Hardy-Weinberg equilibrium (HWE) in the two groups using HAPLOVIEW version 4.2 (http://www.broad.mit.ed u/mpg/haploview). All analyses were conducted under the additive genetic effect as it is the conservative model, using SNPSTATS software (bioinfo.iconcologia.net/snpstats/). Statistical significance was set at P < 0.05.
Results
Pregnancy outcome data
Pregnancy data are summarised in Table 1 . Pregnant women in the two groups were comparable with regard to their age and both occurrence of twin pregnancy and caesarean section. As expected, women with pre-eclampsia had significantly increased SBP and DBP as well as decreased gestational age and infant birthweight. Not surprisingly, women with pre-eclampsia had a significantly higher incidence of primiparous pregnancies and obesity compared with controls, as these are known risk factors for this disease.
Polymorphism association studies
Allele frequencies of Fas A-670G and FasL INV2nt A 124 G polymorphisms were in Hardy-Weinberg equilibrium ( Table 2 ). The frequency of the Fas-670G and FasL INV2nt 124G minor alleles were significantly higher in women with pre-eclampsia compared with controls (P < 0.001). Furthermore, this association was maintained even when we adjusted for body mass index and gestational age (P < 0.001; Table 2 ).
Association analyses
Results obtained in Table 3 demonstrate the relation between carriage of Fas-670 and FasL 124 minor allele on pre-eclampsia features. With regard to Fas-670, carriage of the minor allele was associated with high levels of ASAT (P = 0.033) and ALAT enzymes (P = 0.043). In contrast, there was no association between the FasL INV2nt 124 minor allele with the severity of pre-eclampsia features. Furthermore, carriage of Fas-670 and FasL INV2nt 124 minor alleles showed no association with any of the pre-eclampsia complications evaluated (Table 4) .
Discussion
Main findings
To our knowledge, this study is the first to identify an association between the carriage of the Fas-670G allele and the two hepatic enzymes implicated in the HELLP syndrome (ASAT and ALAT), an important complication associated with severe pre-eclampsia. We are also the first to show an association between the frequency of the G allele for both Fas-670 and FasL INV2nt 124 polymorphism and pre-eclampsia in a Tunisian population.
Strengths and limitations
The strengths of our study are the analysis of the association of Fas A-670G and FasL A 124G variants in a large Tunisian cohort (600 participants) as compared with the few previous studies which were conducted with low case numbers (n = 150). This gives our study higher statistical power for the genetic analysis. Moreover, our population was quite homogeneous (only Tunisian Arab women were involved), which minimises the problems related to differences in genetic background. Limitations in this study are the lack of analysis of other polymorphisms in these genes which are also associated with dysregulation in their expression, as well as the interactions between different SNPs in these genes.
Interpretation
Our results are consistent with a case-controlled study in Hungary by Sziller et al., 18 which investigated the Fas A-670G polymorphism in 38 pregnant women with preeclampsia and 89 normotensive controls. They demonstrated that the maternal −670G allele was associated with an increased risk of pre-eclampsia. It is also in line with the Italian population study by Ciarmela et al. 17 conducted on 50 women with pre-eclampsia and 142 healthy control subjects, which showed that the frequency of the −670G allele was significantly higher (P = 0.029) in women with pre-eclampsia than in healthy subjects. Similarly, Salimi et al. 15 conducted a case-controlled study in an Iranian population of 127 pre-eclampsia and 139 healthy women and reported that the Fas A-670G polymorphism was associated with a higher risk for pre-eclampsia. This is in contrast to the investigation by Masoumi et al. 20 conducted in 153 pre-eclampsia compared with 140 control women recruited from southeast Iran, which found no differences between the two groups with regard to the Fas A-670G polymorphism. Importantly, the results of Salimi et al. 15 may have been influenced by the different ethnic populations involved, as their samples were from Mashhad, located in the northeast of Iran and bordering on Turkmenistan and Afghanistan. In contrast, the samples of Masoumi et al. 20 were all from southeast Iran and might have been more homogeneous. Finally, the only other study which evaluated the association with pre-eclampsia was conducted in Africa, in an Egyptian population, and their results are in agreement with ours, as they also found that the G allele frequency was higher in women with preeclampsia (P = 0.047). 19 The present study is the first to report an association between FasL INV2nt A 124G and the risk of pre-eclampsia. In fact, there are only two other published reports, and they did not find any associations. 17, 19 This may be due to the fact that both of these studies had a smaller number of women with pre-eclampsia (n = 50). In addition, curiously, in the study by Ciarmela et al., 17 men were included in the control group.
Mechanistically, in successful pregnancies, trophoblast cells, which invade the uterine wall during implantation, have high intracellular concentrations of FasL. The FasL on these trophoblasts binds to Fas-expressing activated maternal T lymphocytes and induce their apoptosis, thus protecting the trophoblasts from apoptosis. 25, 26 In pregnancies complicated by pre-eclampsia, the expression of Fas and FasL in sera and on lymphocytes is altered. 27 Miko et al. have shown a lower expression of Fas on T cells in preeclampsia patients than in healthy pregnant women. 28 Our results are consistent with the hypothesis that the failure to induce apoptosis in maternal lymphocytes results in insufficient trophoblast invasion of the spiral arteries. Subsequently, the disturbed FasL-Fas mediated apoptosis resulting from the genetic polymorphism herein could be involved in the pathogenesis of pre-eclampsia. 29 We have shown for the first time the association of Fas-670G with increased levels of the ASAT and ALAT enzymes, which are considered indicators of partial HELLP syndrome in pregnant women with pre-eclampsia. Indeed, diagnosis of the complete form of the HELLP syndrome is characterised by the presence of all three major components, whereas the partial or incomplete form consists of only one or two elements of the components (haemolysis or elevated liver enzymes or low platelets). 21 In severe pre-eclampsia, defective trophoblast invasion and placental ischaemia lead to endothelium damage, which contributes to a further increase in blood pressure and activate the coagulation cascade. This, in turn, causes elevated levels of liver enzymes and renal insufficiency. 30 It has been shown that lymphocytes, as well as liver cells, express FasL and the Fas receptor, which mediate apoptosis of liver cells. Importantly, a study conducted by Sziller et al. 22 indicated that Fas-670G is associated with an increased risk of developing HELLP syndrome in women without pre-eclampsia. This is in line with our results that Fas-670G polymorphism may be associated with partial HELLP syndrome in the context of pre-eclampsia. Put together, the association of this polymorphism with the development of partial HELLP syndrome associated with pre-eclampsia suggests that these women could be at increased risk of maternal and neonatal morbidity and mortality. As such, the assessment of Fas A-670G polymorphism may help predict pregnancy-related complications such as pre-eclampsia and HELLP syndrome.
In contrast to other studies, we did not find an association between IUGR and the Fas-670G allele. Indeed, Sziller et al. 18 reported that the Fas-670G allele was associated with an increased risk of IUGR in American women with pre-eclampsia who delivered before 37 weeks of pregnancy (n = 39). Robinson et al. 31 noted a similar association in American women without pre-eclampsia in a small cohort (n = 50). Interestingly, this group found that this association was present only in white mothers but not in black. Altogether, this suggests that this association with IUGR may be related to a specific population as well as interactions with other environmental factors.
Conclusion
This research supports the hypothesis that the Fas-670G and FasL 124G variants are two important factors that play a role in the development of pre-eclampsia and may be associated with HELLP syndrome. It may be interesting to integrate the screening of these polymorphisms along with other biomarkers to assess the risk of pre-eclampsia during pregnancy. 
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